MedTrace Logo

Everolimus in Treating Patients With Recurrent Low-Grade Glioma

NCT00823459 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2020-07-28

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well everolimus works in treating patients with recurrent low-grade glioma. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

Conditions

  • Adult Diffuse Astrocytoma
  • Adult Mixed Glioma
  • Adult Oligodendroglioma
  • Adult Subependymal Giant Cell Astrocytoma
  • Recurrent Adult Brain Neoplasm

Interventions

DRUG

Everolimus

Given PO

OTHER

Archival Tissue Analysis

Correlative studies

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Susan Chang

    lead OTHER

Principal Investigators

  • Susan Chang, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-23
Primary Completion
2017-06-12
Completion
2017-11-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00823459 on ClinicalTrials.gov